China Oncology ›› 2023, Vol. 33 ›› Issue (6): 605-612.doi: 10.19401/j.cnki.1007-3639.2023.06.008
• Article • Previous Articles Next Articles
Received:
2023-03-31
Revised:
2023-04-16
Online:
2023-06-30
Published:
2023-07-26
Share article
CLC Number:
ZOU Ting, LIU Xiaowen. Analysis of efficacy of hepatectomy and prognostic risk factors in patients with gastric cancer with synchronous liver metastasis[J]. China Oncology, 2023, 33(6): 605-612.
Tab.1
Clinicopathological data of 79 patients with gastric cancer with synchronous liver metastases"
Factor | n (%) | Factor | n (%) | |
---|---|---|---|---|
Gender | Hepatic tumor distribution | |||
Male | 67 (85) | Unilateral | 50 (63) | |
Female | 12 (15) | Bilateral | 28 (36) | |
Age/year | NA | 1 (1) | ||
≤60 | 31 (39) | Metastatic tumor number | ||
>60 | 48 (61) | Single | 41 (52) | |
Primary tumor size D/cm | Multiple | 37 (47) | ||
≤5 | 37 (47) | NA | 1 (1) | |
>5 | 37 (47) | Hepatectomy | ||
NA | 5 (6) | Yes | 34 (43) | |
Location | No | 45 (57) | ||
Upper-middle | 37 (47) | Peritoneal metastasis | ||
Lower | 39 (49) | Yes | 0 (0) | |
NA | 3 (4) | No | 79 (100) | |
Depth of invasion | Serum AFP level at diagnosis | |||
T1-2 | 7 (9) | Normal | 50 (63) | |
T3-4 | 42 (53) | Elevated | 7 (9) | |
NA | 30 (38) | NA | 22 (28) | |
Lymph node metastasis | Serum CEA level at diagnosis | |||
N0-1 | 14 (18) | Normal | 32 (40) | |
N2-3 | 35 (44) | Elevated | 25 (32) | |
NA | 30 (38) | NA | 22 (28) | |
Differentiated degree | Synchronous liver metastases | |||
Well/moderate | 25 (32) | Yes | 79 (100) | |
Poor | 30 (38) | No | 0 (0) | |
NA | 24 (30) | |||
Metastatic tumor size D/cm | ||||
≤3 | 41 (52) | |||
>3 | 7 (9) | |||
NA | 31 (39) |
Tab. 2
Univariate and multivariate analysis of OS in patients with gastric cancer with synchronous liver metastases"
Data | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
P value | HR | 95% CI | P value | ||
Gender | 0.992 | ||||
Age/year | 0.879 | ||||
Primary tumor size D/cm | 0.046 | 0.662 | 0.164-2.666 | 0.562 | |
Location | 0.136 | ||||
Depth of invasion | 0.087 | ||||
Number of lymph nodes | 0.087 | 2.055 | 0.359-11.746 | 0.418 | |
Differentiated degree | 0.001 | 0.185 | 0.034-1.011 | 0.052 | |
Metastatic tumor size D/cm | 0.360 | 0.593 | 0.092-3.812 | 0.582 | |
Hepatic tumor distribution | 0.038 | 37.253 | 2.577-538.447 | 0.008 | |
Metastatic tumor number | 0.456 | 1.790 | 0.303-10.581 | 0.521 | |
Hepatectomy | 0.000 | 0.149 | 0.023-0.948 | 0.044 | |
Serum AFP level at diagnosis | 0.000 | 8.554 | 0.851-86.032 | 0.068 | |
Serum CEA level at diagnosis | 0.149 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] |
FERLAY J, STELIAROVA-FOUCHER E, LORTET-TIEULENT J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012[J]. Eur J Cancer, 2013, 49(6): 1374-1403.
doi: 10.1016/j.ejca.2012.12.027 pmid: 23485231 |
[3] |
SHAH M A, KELSEN D P. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease[J]. J Natl Compr Canc Netw, 2010, 8(4): 437-447.
doi: 10.6004/jnccn.2010.0033 |
[4] |
CONDE MONROY D, IBAÑEZ-PINILLA M, SABOGAL J C, et al. Survival outcomes of hepatectomy in gastric cancer liver metastasis: a systematic review and meta-analysis[J]. J Clin Med, 2023, 12(2): 704.
doi: 10.3390/jcm12020704 |
[5] |
GARANCINI M, UGGERI F, DEGRATE L, et al. Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?[J]. HPB (Oxford), 2012, 14(3): 209-215.
doi: 10.1111/j.1477-2574.2011.00428.x |
[6] |
MIKI Y, FUJITANI K, HIRAO M, et al. Significance of surgical treatment of liver metastases from gastric cancer[J]. Anticancer Res, 2012, 32(2): 665-670.
pmid: 22287760 |
[7] |
ROMANO F, GARANCINI M, UGGERI F, et al. Surgical treatment of liver metastases of gastric cancer: state of the art[J]. World J Surg Oncol, 2012, 10: 157.
doi: 10.1186/1477-7819-10-157 pmid: 22862882 |
[8] |
CHEN L, SONG M Q, LIN H Z, et al. Chemotherapy and resection for gastric cancer with synchronous liver metastases[J]. World J Gastroenterol, 2013, 19(13): 2097-2103.
doi: 10.3748/wjg.v19.i13.2097 |
[9] |
FUJITANI K, YANG H K, MIZUSAWA J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3): 309-318.
doi: S1470-2045(15)00553-7 pmid: 26822397 |
[10] |
GRANIERI S, ALTOMARE M, BRUNO F, et al. Surgical treatment of gastric cancer liver metastases: systematic review and meta-analysis of long-term outcomes and prognostic factors[J]. Crit Rev Oncol Hematol, 2021, 163: 103313.
doi: 10.1016/j.critrevonc.2021.103313 |
[11] | MINCIUNA C E, TUDOR S, MICU A, et al. Safety and efficacy of simultaneous resection of gastric carcinoma and synchronous liver metastasis-a western center experience[J]. Medicina (Kaunas), 2022, 58(12): 1802. |
[12] |
YAMAGUCHI T, TAKASHIMA A, NAGASHIMA K, et al. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage Ⅳ gastric cancer with synchronous oligo metastasis: a multicenter retrospective study[J]. Gastric Cancer, 2023, 26(2): 307-316.
doi: 10.1007/s10120-023-01363-8 |
[13] |
CUI J K, LIU M, SHANG X K. Hepatectomy for liver metastasis of gastric cancer: a meta-analysis[J]. Surg Innov, 2019, 26(6): 692-697.
doi: 10.1177/1553350619856491 |
[14] |
OCHIAI T, SASAKO M, MIZUNO S, et al. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors[J]. Br J Surg, 1994, 81(8): 1175-1178.
doi: 10.1002/bjs.1800810832 |
[15] |
MARTE G, TUFO A, STECCANELLA F, et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: a systematic review of the literature and meta-analysis of prognostic factors[J]. J Clin Med, 2021, 10(5): 1141.
doi: 10.3390/jcm10051141 |
[16] |
OHKURA Y, SHINOHARA H, HARUTA S, et al. Hepatectomy offers superior survival compared with non-surgical treatment for≤3 metastatic tumors with diameters < 3 cm from gastric cancer: a retrospective study[J]. World J Surg, 2015, 39(11): 2757-2763.
doi: 10.1007/s00268-015-3151-0 |
[17] |
OKI E, TOKUNAGA S, EMI Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)[J]. Gastric Cancer, 2016, 19(3): 968-976.
doi: 10.1007/s10120-015-0530-z pmid: 26260876 |
[18] |
WANG Y N, SHEN K T, LING J Q, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases[J]. BMC Surg, 2012, 12: 20.
doi: 10.1186/1471-2482-12-20 |
[19] |
KINOSHITA T, KINOSHITA T, SAIURA A, et al. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases[J]. Br J Surg, 2015, 102(1): 102-107.
doi: 10.1002/bjs.9684 pmid: 25389030 |
[20] |
TIBERIO G A, MINISTRINI S, GARDINI A, et al. Factors influencing survival after hepatectomy for metastases from gastric cancer[J]. Eur J Surg Oncol, 2016, 42(8): 1229-1235.
doi: 10.1016/j.ejso.2016.03.030 pmid: 27134189 |
[21] |
UGGERI F, RIPAMONTI L, PINOTTI E, et al. Is there a role for treatment-oriented surgery in liver metastases from gastric cancer?[J]. World J Clin Oncol, 2020, 11(7): 477-494.
doi: 10.5306/wjco.v11.i7.477 pmid: 32821653 |
[22] |
CHEN J, TANG Z, DONG X, et al. Radiofrequency ablation for liver metastasis from gastric cancer[J]. Eur J Surg Oncol, 2013, 39(7): 701-706.
doi: 10.1016/j.ejso.2013.03.023 pmid: 23597495 |
[23] | ZHANG K C, CHEN L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases[J]. Ther Adv Med Oncol, 2020, 12: 1758835920904803. |
[24] |
KATAOKA K, KINOSHITA T, MOEHLER M, et al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG[J]. Gastric Cancer, 2017, 20(5): 904-912.
doi: 10.1007/s10120-017-0696-7 pmid: 28150070 |
[25] |
VIGANÒ L, VELLONE M, FERRERO A, et al. Liver resection for gastric cancer metastases[J]. Hepato-gastroenterology, 2013, 60(123): 557-562.
pmid: 23635434 |
[26] |
YUKAMI H, KAWAZOE A, LIN Y T, et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials[J]. Clin Cancer Res, 2022, 28(16): 3480-3488.
doi: 10.1158/1078-0432.CCR-22-0630 pmid: 35679062 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd